These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7396763)

  • 1. Influence of uremic middle molecules on blood cells.
    Ota K; Sanaka T; Agishi T; Nakajima O
    Artif Organs; 1980 May; 4(2):113-5. PubMed ID: 7396763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo accumulation of sodium pump inhibitor by normal and uremic erythrocytes.
    Gallice P; Lai E; Brunet P; Berland Y; Elsen R; Crevat A
    Int J Artif Organs; 1993 Mar; 16(3):120-2. PubMed ID: 8390969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of plasma middle molecular fraction in uremic patients.
    Kovalishin YaF
    Biomater Artif Cells Artif Organs; 1987; 15(3):605-10. PubMed ID: 3440134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical analytic approaches to the definition of uremic toxins.
    Furst P; Bergstrom J; Gordon A; Zimmermann L
    Ateneo Parmense Acta Biomed; 1975; 46(5):307-16. PubMed ID: 1232992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of middle molecules on the anemia of uremic patients.
    Leber HW; Spiegelhalter R; Ulm A; Goubeaud G; Rawer P
    Artif Organs; 1978 Nov; 2(4):378-81. PubMed ID: 743010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Examination of lymphokines in patients with hemodialysis (author's transl)].
    Löcsey L; Kálmán K; Hauck M; Kakuk G
    Allerg Immunol (Leipz); 1979; 25(3):211-7. PubMed ID: 162030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technical aspects on middle molecules: separation, isolation, and identification.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():8-12. PubMed ID: 7295100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodology for identification of serum middle molecules.
    Buzio C; Montagna G; Calderini C; Manari A; Migone L
    Artif Organs; 1981; 4 Suppl():22-7. PubMed ID: 7295090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acid composition of uremic middle and low molecular weight retention products.
    Bazilinski N; Shaykh M; Ahmed S; Musiala T; Williams RH; Poulos A; Dubin A; Dunea G
    Adv Exp Med Biol; 1987; 223():197-204. PubMed ID: 3447436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uremic neurotoxin in the middle molecular weight range.
    Man NK; Cueille G; Zingraff J; Boudet J; Sausse A; Funck-Brentano JL
    Artif Organs; 1980 May; 4(2):116-20. PubMed ID: 7396764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of platelet function by uremic middle molecules.
    Bazilinski N; Shaykh M; Dunea G; Mamdani B; Patel A; Czapek E; Ahmed S
    Nephron; 1985; 40(4):423-8. PubMed ID: 4022211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabolism.
    Hsu CH; Vanholder R; Patel S; De Smet RR; Sandra P; Ringoir SM
    Kidney Int; 1991 Nov; 40(5):868-73. PubMed ID: 1762291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of middle molecules with positive reaction to ninhydrin present in uremic and normal blood and their isolation].
    Buzio C; Dall'Aglio PP; Delmonte G; Montagna G; Migone L
    Minerva Nefrol; 1979; 26(1):45-8. PubMed ID: 471320
    [No Abstract]   [Full Text] [Related]  

  • 15. [The anticoagulant activity of the plasma ultrafiltrate as a possible criterion of uremic poisoning].
    Sukhanov VA; Chuzhinov SV; Koriakov IO; Zlokazov VB
    Ter Arkh; 1991; 63(6):68-71. PubMed ID: 1948752
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of uremic plasma fractions of different molecular sizes on the filterability of red blood cells].
    Eggert W; Scigalla P; Noack C; Devaux S; Wolf S
    Z Urol Nephrol; 1981 May; 74(5):391-9. PubMed ID: 7269824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Many hitherto unknown peptides are principal constituents of uremic "middle molecules".
    Menyhárt J; Gróf J
    Clin Chem; 1981 Oct; 27(10):1712-6. PubMed ID: 7285323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat.
    Anderstam B; Mamoun AH; Södersten P; Bergström J
    J Am Soc Nephrol; 1996 Nov; 7(11):2453-60. PubMed ID: 8959639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and identification of canine plasma components suspected as uremic toxins.
    Kawamura M; Ohashi F; Nagata Y; Takai N; Motoie H; Nishimura R; Sasaki N; Takeuchi A
    J Vet Med Sci; 1993 Apr; 55(2):265-70. PubMed ID: 8513007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of blood toxicity in chronic uremia by an improved chromatographic method.
    Politi L; D'Angelo AR; Caramia M; Molinaro M; Nicoletti R; Cerulli N; Moriggi M; Scandurra R
    Clin Exp Dial Apheresis; 1981; 5(3):277-84. PubMed ID: 7333038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.